HSP90AA1 and pachyonychia congenita: Though there is not enough targeting TRAP1 inhibitors for PC treatment, the ATPase in NTD of other Hsp90 inhibitors have similar structure with TRAP1, one has proved that these Hsp90 inhibitors can competitively inactive TRAP1 ATPase in vitro (189), which can be used to develop TRAP1 selective inhibitors in future.